RMD vs. MDT, BDX, EW, IDXX, DXCM, STE, PODD, BAX, HOLX, and GMED
Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.
ResMed vs.
ResMed (NYSE:RMD) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.
Medtronic received 1156 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 75.49% of users gave Medtronic an outperform vote while only 52.74% of users gave ResMed an outperform vote.
ResMed has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.
In the previous week, Medtronic had 16 more articles in the media than ResMed. MarketBeat recorded 41 mentions for Medtronic and 25 mentions for ResMed. Medtronic's average media sentiment score of 1.31 beat ResMed's score of 1.21 indicating that Medtronic is being referred to more favorably in the news media.
ResMed currently has a consensus price target of $249.73, indicating a potential upside of 18.70%. Medtronic has a consensus price target of $96.07, indicating a potential upside of 16.41%. Given ResMed's stronger consensus rating and higher possible upside, equities research analysts plainly believe ResMed is more favorable than Medtronic.
ResMed pays an annual dividend of $2.12 per share and has a dividend yield of 1.0%. Medtronic pays an annual dividend of $2.80 per share and has a dividend yield of 3.4%. ResMed pays out 25.0% of its earnings in the form of a dividend. Medtronic pays out 85.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ResMed has raised its dividend for 13 consecutive years and Medtronic has raised its dividend for 48 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.
55.0% of ResMed shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 0.2% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
ResMed has a net margin of 25.34% compared to Medtronic's net margin of 12.83%. ResMed's return on equity of 26.17% beat Medtronic's return on equity.
Summary
ResMed and Medtronic tied by winning 11 of the 22 factors compared between the two stocks.
Get ResMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:RMD) was last updated on 4/11/2025 by MarketBeat.com Staff
Buy RMD Stock Free RMD Stock Alerts